Fully Human Phage Library
We have obtained several monoclonal antibodies and bi-specific antibodies rapidly screened from the fully human phage library, these antibodies are entering or have been in clinical studies.

Mouse Hybridoma Antibody Humanization
For complicate targets such as GPCR family proteins and targets requiring special antibody functions, mouse hybridoma technology is used to ensure the diversity of candidates, and the final candidates are obtained through humanization technology.

Single Domain Antibody
It is suitable for screening more stable and high-yield single domain antibodies. Single domain antibodies are smaller, more stable than conventional antibodies, and can recognize novel epitopes. Moreover, it has better penetration and accessibility to tumor tissues and microenvironment.

CD3 Engager
Our CD3 Engager platform has a variety of designs for different targets, including binding to TAA with varying expression levels, CD3 affinity fine-tuning and tumor conditional activation, different valency and spatial structure, to achieve balance between efficacy and safety. A couple of CD3 engagers for the treatment of solid and liquid tumors have entered preclinical development stage with strong anti-tumor efficacy and good safety profile in preclinical efficacy models and toxicology studies.

Bifunctional Fusion Protein/Bispecific Antibody
The bifunctional fusion protein and bispecific antibody consist of monoclonal antibody and fusion protein targeting various targets, to achieve bifunctional effects or reduce the side effects through improved tumor targeting. Based on antibody engineering technology, we have currently established unique MabFusion platform, common light chain bispecific antibody platform (CLBI), etc., which can be used for the development of various symmetric bifunctional fusion proteins/bispecific antibodies and asymmetric bi(multi)-specific antibodies.

4-1BB Engager
Our 4-1BB engager platform is developed by utilizing antibody engineering technology to balance the affinity between TAA and 4-1BB, crosslinking and activating the 4-1BB receptor through binding to TAA targets, thereby maximizing the function of targeting the 4-1BB. In in vivo studies have demonstrated that it promotes the activation and proliferation of effector T cells, improves the tumor infiltration, inhibits Treg cells and reverses the TME to boost the immune system and exerts anti-tumor effects, as well as avoids possible hepatotoxicity caused by anti-4-1BB. The project designed based on 4-1BB engager has been validated for its safety and effectiveness in clinical studies.